Rosetta Genomics to Present at Sidoti & Company 2013 Micro-Cap Conference

  Rosetta Genomics to Present at Sidoti & Company 2013 Micro-Cap Conference

PR Newswire

PHILADELPHIA and REHOVOT, Israel, Jan. 4, 2013

PHILADELPHIA and REHOVOT, Israel, Jan. 4, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced that Kenneth A. Berlin,
President and CEO, is scheduled to present a corporate overview at Sidoti &
Company's 2013 Micro-Cap Conference on Monday, January 7, 2013 at The Grand
Hyatt Hotel in New York City.

The Rosetta Genomics presentation is scheduled for 9:20 a.m. Eastern Time. The
Company's presentation will be available on its website at
www.rosettagenomics.com.

About miRview^® Products

miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type
in primary and metastatic cancer including CUP. miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating to
Rosetta's strategic plan, the market acceptance of Rosetta's miRview^® assays,
particularly miRview^® mets^2, Rosetta's capitalization of its microRNA
platform and Rosetta's development of personalized medicine products
constitute forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta's Annual Report
on Form 20-F for the year ended December 31, 2011 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta's views only as of
the date of this release and should not be relied upon as representing its
views as of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.

Company Contact:              Investor Contacts:
Rosetta Genomics              LHA
Ken Berlin, President & CEO   Anne Marie Fields
(215) 382-9000, ext. 326      (212) 838-3777
investors@rosettagenomics.com afields@lhai.com
                              or
                              Bruce Voss
                              (310) 691-7100
                              bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.

Website: http://www.rosettagenomics.com